MGI Pharma reiterated at market outperform by JMP

MGI Pharma, Inc. was reiterated at market outperform with a $33.00 target price by JMP Securities analysts Charles C. Duncan and Anthony Ostrea after the company received an approvable letter for Dacogen. The analysts said timing is uncertain, though, as management indicated the FDA has requested more analysis of Phase III data. MGI Pharma stock closed down $0.64, or 2.37%, at $26.40 on Friday on volume of 3,801,217 shares versus a three-month trailing average of 1,316,130 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.